January 03, 2017
The First Circuit last month upheld the dismissal of a False Claims Act suit against a Medtronic subsidiary, signaling concern that allowing the medical device fraud case to proceed to trial could allow a jury to usurp the U.S. Food and Drug Administration's regulatory power.